- Department of Neurosurgery, UCLA School of Medicine, Los Angeles, CA, United States.
Seyed Ali Khonsary, Department of Neurosurgery, UCLA School of Medicine, Los Angeles, CA, United States.
DOI:10.25259/SNI_184_2023Copyright: © 2023 Surgical Neurology International This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
How to cite this article: Khonsary SA. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Surg Neurol Int 17-Mar-2023;14:91
How to cite this URL: Khonsary SA. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Surg Neurol Int 17-Mar-2023;14:91. Available from: https://surgicalneurologyint.com/surgicalint-articles/12196/
Title : Goodman & Gilman’s The Pharmacological Basis of Therapeutics
Edition : 14th
Edited by : Laurence L. Brunton; Bjorn C. Knollmann
Published by : Mc Graw Hill
ISBN : 978-1-264-25807-9
Hardcover : $188.46
Pages : 1645
Year : 2023
Eighty two years ago, 1941, two specially talented pioneers, Dr. Louis Goodman, M.A., M.D., and Dr. Alfred Gilman, Ph.D. started a unique book to correlate the science of pharmacology with related medical science.
Since then, their legacy has continued to advance the science of pharmacology for helping the clinicians to have better treatment options for patients, and at present, it is considered the “Blue Bible of Pharmacology.”
This one volume edition has been completely revised and updated plus five additional chapters to accommodate the advancement of medicine and pharmacology.
This updated book is compromised of over 600 color illustrations for clearly explaining the topics of discussion. Especially, there is an illustration on page 533 which clearly demonstrates the Ligand-receptor to long-term physical and behavioral changes in the central nervous system (CNS) by endogenous ligand (i.e., release of DA, 5HT, and NE) or serve as ligands themselves (e.g., THC isomers, opioids, and nicotine).
The five new chapters includes: Blood brain barrier, Pharmacovigilance, G.I. Microbiome, and the latest on antibodies and related Immunology.
The book is divided to IX sections on different systems.
Section II is compromised of neuropharmacology consisting of 19 chapters including topics of the latest comprehensive review of neurotransmissions in both autonomic nervous systems, somatic nervous systems, and the CNS.
In addition, there is a chapter on the blood–brain barrier and its influence on drug transport to the brain.
There is a chapter on pharmacotherapy of the epilepsies which are very concise and well categorized to explain the newer anti-seizure medications.
The chapter on degenerative disorders of CNS is classified on Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and amyotrophic lateral sclerosis with related therapeutics.
Section VIII consists of pharmacotherapy of neoplastic diseases which include different classes of anti-cancer therapies with their mechanisms of actions for different categories of cancers including brain tumors (e.g., glioblastoma multiforme).
This book is a necessary armamentarium for the physician-scientists who would like to be up-to-date on the latest therapeutic options for their patients and their related research.
Declaration of patient consent
Patient’s consent is not required as there are no patients in this study.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Journal or its management. The information contained in this article should not be considered to be medical advice; patients should consult their own physicians for advice as to their specific medical needs.